# Immunogenicity, Safety, Tolerability of a Plant-Made H5 VLP Influenza Vaccine

> **NCT01244867** · PHASE2 · COMPLETED · sponsor: **Medicago** · enrollment: 255 (actual)

## Conditions studied

- Virus Diseases
- RNA Virus Infections
- Respiratory Tract Diseases
- Respiratory Tract Infections

## Interventions

- **BIOLOGICAL:** 20 micrograms dose H5 VLP
- **BIOLOGICAL:** 30 micrograms dose H5 VLP
- **BIOLOGICAL:** 45 micrograms dose H5 VLP
- **BIOLOGICAL:** 45 micrograms non-adjuvanted H5 VLP
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01244867
- **Lead sponsor:** Medicago
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2011-07
- **Final completion:** 2011-09
- **Target enrollment:** 255 (ACTUAL)
- **Last updated:** 2012-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01244867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01244867, "Immunogenicity, Safety, Tolerability of a Plant-Made H5 VLP Influenza Vaccine". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01244867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*